Integrity Applications, Inc. (OTCMKTS:IGAP) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure
On October 23, 2017,the Chief Executive Officer (the “CEO”) of Integrity Applications, Inc.(the “Company”) sent a letter to its shareholders to provide a six-month review and updates of the Company’s business. On the same day, the Company published a press release regarding its strategic corporate update for the near term.
Copies of the letter from the CEO and the press release are attached hereto as Exhibits 99.1 and 99.2, respectively. The information contained in this item and the exhibits attached herewith shall be deemed furnished and not filed.
Section 9 – Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits
Integrity Applications, Inc. ExhibitEX-99.1 2 exhibit_99-1.htm EXHIBIT 99.1 Exhibit 99.1 Letter from the CEO to Shareholders Dear Shareholders,…To view the full exhibit click
About Integrity Applications, Inc. (OTCMKTS:IGAP)
Integrity Applications, Inc. is a medical device company. The Company is focused on the design, development and commercialization of non-invasive glucose monitoring devices for use by persons suffering from diabetes. It has developed a non-invasive blood glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes obtain blood glucose level readings without the pain, inconvenience, cost and difficulty of conventional (invasive) spot finger stick devices. The Company operates in Europe, and Asia and Pacific. The GlucoTrack model DF-F utilizes a combination of ultrasound, electromagnetic and thermal technologies to obtain blood glucose measurements in less than one minute through a small sensor that is clipped onto one’s earlobe and connected to a small, handheld control and display unit, all without drawing blood.